about
Type 2B von Willebrand's disease due to Val1316Met mutation. Heterogeneity in the same sibship.Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review.Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity.Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey.Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study.Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors.Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey.Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies.Replacement therapy in inherited factor VII deficiency: occurrence of adverse events and relation with surgery.Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients.Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders.Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm.Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors.A novel mutation in ADAMTS13 of a child with Upshaw-Schulman SyndromeComplement in hematological neoplasiasAcquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cellsvon Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibshipPlatelet and plasma von Willebrand factor: structural differences[Effect of different lectins on the activity of the alternate pathway of complement][The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SType 2M von Willebrand disease: a variant of type 2A?[Lessons about recombinant activated factor VII. Ten years since its registration for use in hemophilia complicated with inhibitor]Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study
P50
Q33338315-8EA20EC1-14C5-4A38-84DF-28504FEC6D7EQ33417764-3DBD5CD2-36C4-41A6-82FF-178B0E284EFAQ33423583-CAFDDE69-137C-40D5-82E7-BD5D64D8D8C8Q33424718-7CFA42B9-E25C-4D3A-B0C3-FA4C69B0C377Q33441053-D2A557CD-F4FF-4C8A-ACAC-1561751E1DB6Q37175593-B7A6FB5C-2957-41F8-8133-8D9322E1E57AQ37604857-72C94E0A-35B4-4ADC-B58D-C3DA1D4F0486Q37732394-9C4ADE32-30AA-43A5-9310-360E9D5F5EACQ38682218-E0D17C31-24C3-4EF8-91B5-241E5C05437BQ38862777-4AC69FC8-1A47-417C-9ECA-2B8754588970Q43165393-8ECED0D1-7DCC-4C11-81E2-79998FB3D041Q45867275-758588E3-E302-4366-BF31-12FAE035232AQ45878364-1D7ECBC7-A200-49AF-9298-B31E3EE72D04Q45884320-4A9066AD-A372-4586-BD04-5D6E96219990Q47165791-46123AEB-60DE-415B-A1AE-085E7D18634BQ47689771-9900D6F3-F02D-45C1-BEB4-1F97AB9040F9Q50123382-E455964A-3AE9-4137-B5DA-41AFAC327018Q53276522-014A41C1-520C-43CD-9DD0-92940E9CE790Q57743565-7DC1D962-F916-47D1-B690-BDF7CCA1FBC4Q66919074-C7E7CB67-8CBF-48C5-B687-11BD6EDFE568Q68540926-3CC6E990-E356-4B27-BE28-2637057E0749Q68792876-46609C18-56FD-4D2D-A3C1-2D62BE8CCBF0Q68810216-4D613554-37A5-4DA2-B0F3-29C7B5AE51D4Q71640955-9A8EEDE9-ACBC-41D1-AAD2-3A13CBDF4156Q79187376-8F2F9250-387C-4189-AC9D-CF12DDC8BBB9Q79954036-A0DC2345-8115-401E-A158-5C7BC2EB106EQ81395117-7C66EC15-9422-438D-A1E0-182E35EFDA83Q84348379-5E73DDE3-14AD-4FE8-8075-5E685F20E1A1
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
López Fernández MF
@ast
López Fernández MF
@es
López Fernández MF
@nl
Maria Fernanda López Fernández
@en
type
label
López Fernández MF
@ast
López Fernández MF
@es
López Fernández MF
@nl
Maria Fernanda López Fernández
@en
altLabel
López Fernández MF
@en
prefLabel
López Fernández MF
@ast
López Fernández MF
@es
López Fernández MF
@nl
Maria Fernanda López Fernández
@en
P31
P496
0000-0003-2492-1843